UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 敗血症に対する治験剤および無効剤 investigational and ineffective therapies for sepsis
2. 敗血症性ショック：小児における蘇生後の継続的マネージメント septic shock ongoing management after resuscitation in children
3. 血漿分画製剤および組換えDNA産生凝固因子 plasma derivatives and recombinant dna produced coagulation factors
4. 成人における播種性血管内凝固の臨床的特徴、診断、および治療 clinical features diagnosis and treatment of disseminated intravascular coagulation in adults
5. 小児における全身性炎症反応症候群（SIRS）および敗血症：定義、疫学、臨床症状、および診断 systemic inflammatory response syndrome sirs and sepsis in children definitions epidemiology clinical manifestations and diagnosis

English Journal

Wiedermann CJ.
Medizinische Klinik, Intensivmedizin und Notfallmedizin.Med Klin Intensivmed Notfmed.2014 Nov;109(8):583-90. doi: 10.1007/s00063-014-0379-7. Epub 2014 Oct 22.
BACKGROUND: Recent decades have been characterized by a large number of trials for registration of new drugs or indication approvals in the field of sepsis. Modern anti-inflammatory drugs or interventions are intended to correct the overwhelming dysregulation of inflammatory and coagulation pathways
PMID 25330980

Hranjec T1, Sawyer RG.
Surgical infections.Surg Infect (Larchmt).2014 Oct;15(5):474-8. doi: 10.1089/sur.2013.154. Epub 2014 May 19.
Abstract Background: Critically ill patients have an increased risk of developing infections and infectious complications, sometimes followed by death. Despite a substantial investment of resources in outcomes improvement, optimum treatment for such patients remains unclear for practicing intensivis
PMID 24841214

Annane D.
Critical care medicine.Crit Care Med.2014 Jul;42(7):1743-4. doi: 10.1097/CCM.0000000000000385.
PMID 24933058

Drotrecogin alfa (activated) treatment in severe sepsis from the global openlabel trial ENHANCE : further evidence for survival and safety and implications for early treatment

中村司,川越康博,松田隆晴
日本アフェレシス学会雑誌 23(1), 80-87, 2004-02-29
… Recently, various treatments including polymyxin B-immobilized fiber (PMX-F), fluconazole, selective inhibitor of group IIA secretory phospholipase A 2, recombinant human granulocyte colony-stimulating factor, drotrecogin alfa (activated) and recombinant tissue factor pathway inhibitor were reported. …
NAID 110003144605